Sunday, March 4, 2018
Health Canada Clarifies Risk Classification Process in Drug Manufacturing Site Inspections
Health Canada has published a risk classification guide to clarify the process of inspecting manufacturing sites for drug manufacturers.
The new Good Manufacturing Practices Guide (GMP) provides information to ensure consistency in the approach used by inspectors to categorize one of the three risk categories: critical observation (risk 1), major observation (risk 2) or other observation (risk 3) for each observation of non-compliance found during the inspections of the drug manufacturing facilities.
Situations identified during inspections that may present immediate or imminent health risks, and / or involve fraud, misrepresentation or falsification of processes, would fall into the category of critical observations. Those that indicate possible production inconsistencies with the marketing authorizations of medicines are important observations. All other observations are minor GMP nonconformities.
However, observations on risks 2 and 3 can be improved in risk 1 or 2, according to the 30-page guidance document, which provides examples of non-compliance for each level.
The guidelines also describe the process used for the inspector's general inspection qualifications based on the risks associated with the observations.
"It is impossible to predict all situations that could create a risk," but inspectors generally follow a two-step process: assign a risk based on the nature of the product evaluated and the non-compliance, as well as the number of differences; and seek immediate corrective action when a risk 1, or risk 2 reassessed as risk 1, is in question, according to Health Canada. "If a company wishes to challenge the results of the final score inspection report, the dispute methods will be described in the letter accompanying the final exit notices without qualification," the regulator added.
Monday, February 26, 2018
FDA Finalizes ICH Q&A Guideline on Drug Substance Manufacturing
The United States Food and Drug Administration (FDA) finalized on Friday its version of the Questions and Answers of the International Council on Harmonization (ICH) in addition to the ICH Guidelines for the Development and Manufacture of Substances of Drugs.
The FDA consulted the draft of the question and answer document in February 2017 and, after consultation and other similar consultations of other Members of the ICH Regulations, the ICP Assembly approved the document in August 2017.
Specifically, the Q & A Guide aims to develop the 2012 ICH guide on drug manufacturing, substance development and drug manufacturing (chemical entities and biotechnological / biological entities).
According to the FDA, the question and answer document provides "additional clarifications and favors the convergence on considerations for the selection and justification of the starting materials" for the manufacture of medicines, with a focus on the synthesis of chemical drugs.
The guide, which is the same as the version approved by ICH in August, includes answers to 16 questions on the justification and selection of starting materials, as well as two decision trees focused on the evaluation of a proposed starting substance. an impact on the profile of impurities of the drug substance.
The FDA consulted the draft of the question and answer document in February 2017 and, after consultation and other similar consultations of other Members of the ICH Regulations, the ICP Assembly approved the document in August 2017.
Specifically, the Q & A Guide aims to develop the 2012 ICH guide on drug manufacturing, substance development and drug manufacturing (chemical entities and biotechnological / biological entities).
According to the FDA, the question and answer document provides "additional clarifications and favors the convergence on considerations for the selection and justification of the starting materials" for the manufacture of medicines, with a focus on the synthesis of chemical drugs.
The guide, which is the same as the version approved by ICH in August, includes answers to 16 questions on the justification and selection of starting materials, as well as two decision trees focused on the evaluation of a proposed starting substance. an impact on the profile of impurities of the drug substance.
Sunday, February 18, 2018
Imfinzi Approved to Reduce Risk of NSCLC Progression
AstraZeneca Immunotherapy Imfinzi (durvalumab) is now approved to reduce the risk of progression of non-small cell lung cancer (NSCLC) in patients with stage III disease whose tumor can not be removed surgically after chemotherapy treatment and radiation therapy that stops cancer with spread."This is the first approved treatment for NSCLC in Phase III, to reduce the risk of cancer progression, when the cancer has not worsened after chemoradiotherapy," said Richard Pazdur, director of knowledge in oncology at the FDA.
According to Pazdur, while some patients will be cured of the disease after chemotherapy and radiation therapy, the cancer will eventually increase for most patients.
The FDA granted in May 2017 for the first time accelerated Imfinzi approval to treat certain patients with locally advanced or metastatic bladder cancer. The FDA also states that both the priority review that the breakthrough has granted the additional license of biological products (sBLA) AstraZeneca for the new indication.
The FDA said it based the decision to expand the Imfinzi-based label on a randomized study of 713 patients measured progression-free survival (PFS) in patients who had Imfinzi and patients using placebo. In the study, the median PFS for patients using Imfinzi was three times longer than for patients receiving placebo, 16.8 months versus 5.6 months.
With the expanded label, the FDA states that AstraZeneca has accepted a post-marketing commitment (PMC) to provide the organization with the overall survival data of patients who participated in the study.
Sunday, February 11, 2018
Regulatory Reform: Companies and Industry Groups Offer up a Wish List of CDER, CDRH Changes
Johnson & Johnson (J & J) and Abbott, as well as the PhRMA, BIO and AdvaMed industry group presented their priorities for the US Food and Drug Administration's (FDA) call to amend, repeal or replace regulations , according to comments Thursday on the register.
J & J have compiled a list of seven priorities that have been tabled for both CDER and CDRH, including reforms to simplify the way in which information from manufacturers who are not on a product label are disclosed; approval allow for changes to a label without FDA clearance, reducing conflicts of interest for FDA advisory committees (which PhRMA had also requested) and increasing the use of electronic labeling rather than paper.
J & J is also reviewing the FDA's decision to pause a voluntary quality data reporting program via an FDA portal after the industry has called on the agency to take the break.
"We are in agreement with the FDA that manufacturers of quality data to collect and analyze, but collects each company and analyze the data in its own way and adhering to a one-size-fits-all approach requires changes in heavy process. Cosmetic Act authorizes the FDA to require companies to collect data and submit the prescribed formats. We are compliant with the current pause in the additional input program from stakeholders and suggest that manufacturers should not enter to present data quality and statistics these data must be available for review during inspections, "says the comment.
PhRMA also called for changes in the FDA's guidelines on human factors research in the comments of the CDRH, while BIO called for regulatory changes for genetically modified animals.
Mutual approvals and inspections
J & J also suggests that mutual FDA approval of medical devices with the EU allows a medical device "class III ... save lives of vanguard additional data would be postmarketing place to access the patient's treatment options While the commitment is maintained The FDA requirements for Subparts B and C of 21 CFR 814 must be revised to reflect this approach. "
Abbott is appealing to the FDA to withdraw a proposed rule on the electronic submission of labels for certain home appliances that, in its opinion, is "superfluous because the labeling of devices is necessary to accompany medical devices used in distribution commercial. widely available to users and many home appliance manufacturers provide product labeling information on their websites. "
The AdvaMed group of Device Industry made 19 recommendations, covering everything from revisions to the use of symbols in the labeling rule, asking the FDA to consider a paper assessment rather than a prior on-site approval. .
"The increased use of evaluation by the production section of an LDC would save time. Approval inspections are intensive in terms of time and resources, "said the group, suggesting that a change could save $ 10 million.
J & J have compiled a list of seven priorities that have been tabled for both CDER and CDRH, including reforms to simplify the way in which information from manufacturers who are not on a product label are disclosed; approval allow for changes to a label without FDA clearance, reducing conflicts of interest for FDA advisory committees (which PhRMA had also requested) and increasing the use of electronic labeling rather than paper.
J & J is also reviewing the FDA's decision to pause a voluntary quality data reporting program via an FDA portal after the industry has called on the agency to take the break.
"We are in agreement with the FDA that manufacturers of quality data to collect and analyze, but collects each company and analyze the data in its own way and adhering to a one-size-fits-all approach requires changes in heavy process. Cosmetic Act authorizes the FDA to require companies to collect data and submit the prescribed formats. We are compliant with the current pause in the additional input program from stakeholders and suggest that manufacturers should not enter to present data quality and statistics these data must be available for review during inspections, "says the comment.
PhRMA also called for changes in the FDA's guidelines on human factors research in the comments of the CDRH, while BIO called for regulatory changes for genetically modified animals.
Mutual approvals and inspections
J & J also suggests that mutual FDA approval of medical devices with the EU allows a medical device "class III ... save lives of vanguard additional data would be postmarketing place to access the patient's treatment options While the commitment is maintained The FDA requirements for Subparts B and C of 21 CFR 814 must be revised to reflect this approach. "
Abbott is appealing to the FDA to withdraw a proposed rule on the electronic submission of labels for certain home appliances that, in its opinion, is "superfluous because the labeling of devices is necessary to accompany medical devices used in distribution commercial. widely available to users and many home appliance manufacturers provide product labeling information on their websites. "
The AdvaMed group of Device Industry made 19 recommendations, covering everything from revisions to the use of symbols in the labeling rule, asking the FDA to consider a paper assessment rather than a prior on-site approval. .
"The increased use of evaluation by the production section of an LDC would save time. Approval inspections are intensive in terms of time and resources, "said the group, suggesting that a change could save $ 10 million.
Monday, February 5, 2018
Falsified Medicines: EC Report Finds Inconsistent Penalties Throughout the EU
A recent European Commission (EC) report shows that although all EU Member States have implemented laws in accordance with the Falsified Medicines Directive, sanctions for violating these laws vary considerably from one country to another. country to another.
"Sanctions are only effective if they are properly implemented and I urge all EU countries to ensure that criminals who falsify drugs are punished," said Vytenis Andriukaitis, European Commissioner for Health and food security. ensure that criminals catch counterfeit drugs are punished.
According to the report, the maximum imprisonment penalty for falsifying a drug of only one year varies between Sweden, Finland and Greece at age 15 in Austria, Slovenia and Slovakia.
The maximum penalties for the counterfeiting of a medicine range from € 4,300 in Lithuania to € 1 million in Spain. In the United Kingdom, there is no maximum for such fines.
Similarly, maximum prison sentences and misconduct penalties for active substances and excipients vary considerably from one Member State to another.
In addition, the specification differs from what has been criminalized from one Member State to another. For example, Latvia sanctions drug falsification resulting in bodily injury or death, while most Member States criminalize falsification "without the need to prove that the product is dangerous to health" .
The report also notes that it is "difficult to measure the effectiveness of specific national sanctions because of a lack of comprehensive data on incidents in the Member States".
However, experts consulted before the report told the EC that the sanctions "had at least one effect on reducing the presence of counterfeit drugs in the legal distribution chain," but described the administrative sanctions as the most effective deterrent.
But with regard to the sale of illegal drugs, the experts found that criminal sanctions were a more effective deterrent.
As such, the report recommends that Member States introduce additional administrative and criminal penalties for falsified medicines and request countries to reserve sufficient resources to maintain these sanctions.
"Sanctions are only effective if they are properly implemented and I urge all EU countries to ensure that criminals who falsify drugs are punished," said Vytenis Andriukaitis, European Commissioner for Health and food security. ensure that criminals catch counterfeit drugs are punished.
According to the report, the maximum imprisonment penalty for falsifying a drug of only one year varies between Sweden, Finland and Greece at age 15 in Austria, Slovenia and Slovakia.
The maximum penalties for the counterfeiting of a medicine range from € 4,300 in Lithuania to € 1 million in Spain. In the United Kingdom, there is no maximum for such fines.
Similarly, maximum prison sentences and misconduct penalties for active substances and excipients vary considerably from one Member State to another.
In addition, the specification differs from what has been criminalized from one Member State to another. For example, Latvia sanctions drug falsification resulting in bodily injury or death, while most Member States criminalize falsification "without the need to prove that the product is dangerous to health" .
The report also notes that it is "difficult to measure the effectiveness of specific national sanctions because of a lack of comprehensive data on incidents in the Member States".
However, experts consulted before the report told the EC that the sanctions "had at least one effect on reducing the presence of counterfeit drugs in the legal distribution chain," but described the administrative sanctions as the most effective deterrent.
But with regard to the sale of illegal drugs, the experts found that criminal sanctions were a more effective deterrent.
As such, the report recommends that Member States introduce additional administrative and criminal penalties for falsified medicines and request countries to reserve sufficient resources to maintain these sanctions.
Sunday, January 28, 2018
FDA Publishes First Performance Metrics for Third Party 510(k) Reviews
The US Food and Drug Administration (FDA) on Friday published the first of its quarterly performance reports for accredited third party reviewers for certain medical device submissions.
Background
FDA's third party accredited persons program was created by the 1997 FDA Modernization Act (FDAMA) as a means of making the review process for certain low-risk devices submitted under a 510(k) more timely and efficient.
Under the program, device makers can submit 510(k)s for eligible devices to accredited third parties that conduct the primary review of the submission before forwarding their recommendation to FDA, which makes a final determination on the recommendation within 30 days.
There are currently seven accredited third party reviewed under the program based in the US, China and Norway.
Performance Metrics
While FDA's third party accredited persons program has been operational for roughly two decades, the agency had not released performance data for individual third party reviewers until this year, after committing to do so in the recently reauthorized Medical Device User Fee Amendments (MDUFA IV).
However, under MDUFA IV, FDA only agreed to publish performance data for third party reviewers that have completed a minimum of five reviews during the reporting period, which at the time of the agency's first report includes just one third party reviewer: Regulatory Technology Services (RTS).
The report itself features a box plot detailing the performance of the individual third party reviewers for six different metrics:
In total, FDA says there have been 18 third party 510(k) submissions in FY2018, eight of which have been completed and found substantially equivalent to a predicate device, and ten of which are still pending a final decision by FDA.
Of the ten pending decisions, nine are still within the 30-day window for FDA to issue a determination, while one has been pending for more than 30 days.
For the third party reviews themselves, FDA says the average total time to decision from the time a third party reviewer receives a submission to when FDA issues its final determination is 80 days, with an interquartile range of 52 to 94 days and the longest review taking 172 days.
Background
FDA's third party accredited persons program was created by the 1997 FDA Modernization Act (FDAMA) as a means of making the review process for certain low-risk devices submitted under a 510(k) more timely and efficient.
Under the program, device makers can submit 510(k)s for eligible devices to accredited third parties that conduct the primary review of the submission before forwarding their recommendation to FDA, which makes a final determination on the recommendation within 30 days.
There are currently seven accredited third party reviewed under the program based in the US, China and Norway.
Performance Metrics
While FDA's third party accredited persons program has been operational for roughly two decades, the agency had not released performance data for individual third party reviewers until this year, after committing to do so in the recently reauthorized Medical Device User Fee Amendments (MDUFA IV).
However, under MDUFA IV, FDA only agreed to publish performance data for third party reviewers that have completed a minimum of five reviews during the reporting period, which at the time of the agency's first report includes just one third party reviewer: Regulatory Technology Services (RTS).
The report itself features a box plot detailing the performance of the individual third party reviewers for six different metrics:
- Initial third party review time
- Third party hold time
- Total third party review time
- Total FDA review time
- Total time to decision from FDA
- Total time to decision from third party receipt
In total, FDA says there have been 18 third party 510(k) submissions in FY2018, eight of which have been completed and found substantially equivalent to a predicate device, and ten of which are still pending a final decision by FDA.
Of the ten pending decisions, nine are still within the 30-day window for FDA to issue a determination, while one has been pending for more than 30 days.
For the third party reviews themselves, FDA says the average total time to decision from the time a third party reviewer receives a submission to when FDA issues its final determination is 80 days, with an interquartile range of 52 to 94 days and the longest review taking 172 days.
Sunday, January 14, 2018
FDA Warns BD Over Changes Made to Blood Collection Tubes in Lead Testing Investigation
After examining the cause of the faulty lead test of four of Magellan Diagnostics LeadCare test systems last May, the Food and Drug Administration (FDA) warned Becton Dickinson (BD) on Thursday that it has not submitted a new lead test. 510 (k) for changes in his blood collection tubes.
At the beginning of the study, Jeffrey Shuren, director of the Center for Apparatus and Radiological Health (CDRH), said that the agency tried to determine the cause of the inaccurate test results, but still did not know these problems because of differences in blood. samples are collected, tubes are used to hold blood or a change in the way samples are processed.
As part of the investigation, the FDA inspected BD facilities in Franklin Lakes, New Jersey, where it produces Vacutainer blood collection tubes for three weeks in May and June.
"Our inspection has shown that BD has violated the law by making major changes to certain devices ... without notifying the FDA and not following good manufacturing practices," said Donald St. Pierre, Deputy Director of Evaluation. new products on CDRH. The FDA also stated that BD had not investigated a 2015 Magellan complaint regarding "observed negative bias" in test results with Magellan's LeadCare test systems when using Vacutainer tubes.
"Your company did not record this information in the complaints system, did not evaluate the complaint to determine whether this was a reportable event, or started an investigation into the complaint," the FDA wrote.
Although the FDA has stated that changes in the composition of rubber stoppers used with Vacutainer tubes may cause new interference with laboratory tests and lead to biased results, the agency said it was uncertain.
In a statement released on Friday, Richard Byrd, president of BD's pre-analytical systems, said the company was working with the FDA and thought the company was responding fully to the agency's inspection observations.
Update on BD spraying
On Friday, the FDA also announced that BD has stopped using rubber stoppers in its syringes, which reduces the power of the drug.
In September 2015, the FDA warned health professionals against the use of BD general-purpose syringes with compounded or reconditioned drugs stored in syringes due to the potential of drugs that interact with the rubber stopper in the syringe.
Although the FDA has approved approved syringes for general aspiration and injection of fluids, they are not authorized to be used as closed container storage systems for pharmaceuticals.
Now the FDA has declared that BD has stopped the rubber stopping material with regard to the power loss of the medicine and has returned with a rubber stopper used in other syringes.
Healthcare professionals should contact BD to determine if specific batches of syringes contain the new caps.
At the beginning of the study, Jeffrey Shuren, director of the Center for Apparatus and Radiological Health (CDRH), said that the agency tried to determine the cause of the inaccurate test results, but still did not know these problems because of differences in blood. samples are collected, tubes are used to hold blood or a change in the way samples are processed.
As part of the investigation, the FDA inspected BD facilities in Franklin Lakes, New Jersey, where it produces Vacutainer blood collection tubes for three weeks in May and June.
"Our inspection has shown that BD has violated the law by making major changes to certain devices ... without notifying the FDA and not following good manufacturing practices," said Donald St. Pierre, Deputy Director of Evaluation. new products on CDRH. The FDA also stated that BD had not investigated a 2015 Magellan complaint regarding "observed negative bias" in test results with Magellan's LeadCare test systems when using Vacutainer tubes.
"Your company did not record this information in the complaints system, did not evaluate the complaint to determine whether this was a reportable event, or started an investigation into the complaint," the FDA wrote.
Although the FDA has stated that changes in the composition of rubber stoppers used with Vacutainer tubes may cause new interference with laboratory tests and lead to biased results, the agency said it was uncertain.
In a statement released on Friday, Richard Byrd, president of BD's pre-analytical systems, said the company was working with the FDA and thought the company was responding fully to the agency's inspection observations.
Update on BD spraying
On Friday, the FDA also announced that BD has stopped using rubber stoppers in its syringes, which reduces the power of the drug.
In September 2015, the FDA warned health professionals against the use of BD general-purpose syringes with compounded or reconditioned drugs stored in syringes due to the potential of drugs that interact with the rubber stopper in the syringe.
Although the FDA has approved approved syringes for general aspiration and injection of fluids, they are not authorized to be used as closed container storage systems for pharmaceuticals.
Now the FDA has declared that BD has stopped the rubber stopping material with regard to the power loss of the medicine and has returned with a rubber stopper used in other syringes.
Healthcare professionals should contact BD to determine if specific batches of syringes contain the new caps.
Subscribe to:
Posts (Atom)

